Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Nausea and Vomiting

Alliance for Clinical Trials in OncologySmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

8 Active assets in the Nausea and Vomiting cohort.

Asset / SponsorPhaseRating
Palonosetron
Jiuda Zhao
Phase 3BB
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Jiuda Zhao
Phase 3BB
Zofran
Jiuda Zhao
Phase 3BB
DEXAMETHASONE
Jiuda Zhao
Phase 3BB
Granisetron
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 24 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →